Advertisement
Advertisement
U.S. markets close in 3 hours 51 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BELLUS Health Inc. (BLU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
7.98+0.12 (+1.53%)
As of 12:08PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close7.86
Open7.82
Bid7.95 x 800
Ask7.97 x 900
Day's Range7.86 - 8.04
52 Week Range5.45 - 12.69
Volume174,323
Avg. Volume581,298
Market Cap1.014B
Beta (5Y Monthly)-0.47
PE Ratio (TTM)N/A
EPS (TTM)-0.81
Earnings DateFeb 21, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.56
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BLU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BELLUS Health Inc.
    Daily – Vickers Top Insider Picks for 12/15/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Simply Wall St.

    BELLUS Health Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

    BELLUS Health ( TSE:BLU ) Third Quarter 2022 Results Key Financial Results Net loss: US$24.7m (loss widened by 8.0...

  • Business Wire

    BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights

    LAVAL, Quebec, November 14, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitivity indications, today reported its financial and operating results for the third quarter ended September 30, 2022.

  • Business Wire

    BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences

    LAVAL, Quebec, November 10, 2022--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in two upcoming healthcare investor conferences.

Advertisement
Advertisement